Silvy Lachance

2.0k total citations
67 papers, 616 citations indexed

About

Silvy Lachance is a scholar working on Hematology, Oncology and Immunology. According to data from OpenAlex, Silvy Lachance has authored 67 papers receiving a total of 616 indexed citations (citations by other indexed papers that have themselves been cited), including 49 papers in Hematology, 33 papers in Oncology and 15 papers in Immunology. Recurrent topics in Silvy Lachance's work include Hematopoietic Stem Cell Transplantation (43 papers), CAR-T cell therapy research (17 papers) and Multiple Myeloma Research and Treatments (13 papers). Silvy Lachance is often cited by papers focused on Hematopoietic Stem Cell Transplantation (43 papers), CAR-T cell therapy research (17 papers) and Multiple Myeloma Research and Treatments (13 papers). Silvy Lachance collaborates with scholars based in Canada, France and Germany. Silvy Lachance's co-authors include Thomas Kiss, Sandra Cohen, Jean Roy, Denis‐Claude Roy, Guy Sauvageau, Lambert Busque, Imran Ahmad, Jean‐Sébastien Delisle, Annie‐Claude Labbé and David Steffen and has published in prestigious journals such as Journal of Clinical Oncology, Blood and American Journal of Epidemiology.

In The Last Decade

Silvy Lachance

63 papers receiving 601 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Silvy Lachance Canada	15	331	240	178	118	86	67	616
Patricia Walker Australia	14	248 0.7×	144 0.6×	137 0.8×	192 1.6×	81 0.9×	54	628
Philipp Schütt Germany	13	180 0.5×	239 1.0×	197 1.1×	101 0.9×	70 0.8×	23	594
Alice Garnier France	15	391 1.2×	220 0.9×	202 1.1×	83 0.7×	45 0.5×	73	653
Sakhila Ghimire Germany	10	387 1.2×	157 0.7×	311 1.7×	140 1.2×	109 1.3×	20	692
Marie Thérèse Rubio France	14	229 0.7×	182 0.8×	224 1.3×	129 1.1×	47 0.5×	39	561
Fábio R. Kerbauy Brazil	11	291 0.9×	153 0.6×	87 0.5×	48 0.4×	53 0.6×	45	474
Sameem Abedin United States	18	378 1.1×	220 0.9×	187 1.1×	332 2.8×	75 0.9×	68	890
Mohamad Sobh France	14	230 0.7×	131 0.5×	74 0.4×	60 0.5×	102 1.2×	61	476
Sema Anak Türkiye	16	193 0.6×	150 0.6×	103 0.6×	123 1.0×	75 0.9×	73	629
Masatoshi Sakurai Japan	13	204 0.6×	118 0.5×	64 0.4×	105 0.9×	93 1.1×	69	497

Countries citing papers authored by Silvy Lachance

Since Specialization

Citations

This map shows the geographic impact of Silvy Lachance's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Silvy Lachance with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Silvy Lachance more than expected).

Fields of papers citing papers by Silvy Lachance

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Silvy Lachance. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Silvy Lachance. The network helps show where Silvy Lachance may publish in the future.

Co-authorship network of co-authors of Silvy Lachance

This figure shows the co-authorship network connecting the top 25 collaborators of Silvy Lachance. A scholar is included among the top collaborators of Silvy Lachance based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Silvy Lachance. Silvy Lachance is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Jamani, Kareem, Mohamed Elemary, Ivan Pašić, et al.. (2025). Real-world Canadian data on belumosudil therapy in heavily pretreated patients with steroid-refractory chronic graft-versus-host disease: treatment outcomes and risk factor analysis for failure-free survival. Annals of Hematology. 104(10). 5403–5413.

Roy, Jean, Sandra Cohen, Guy Sauvageau, et al.. (2024). A Pilot Study of UM171-Expanded Cord Blood Grafts for Tandem Auto/Allogeneic Hematopoietic Cell Transplant in High and Ultra-High-Risk Myeloma Patients. Transplantation and Cellular Therapy. 31(1). 34.e1–34.e14.

Lachance, Silvy, et al.. (2024). Real-world barriers to CAR-T access: A Canadian referral center perspective.. Journal of Clinical Oncology. 42(16_suppl). e19002–e19002. 1 indexed citations

Kim, Dennis Dong Hwan, Gizelle Popradi, Kristjan Paulson, et al.. (2024). Cell Therapy Transplant Canada (CTTC) Consensus-Based Guideline 2024 for Management and Treatment of Chronic Graft-Versus-Host Disease and Future Directions for Development. Current Oncology. 31(3). 1426–1444. 1 indexed citations

LeBlanc, Richard, Imran Ahmad, Jean‐Sébastien Delisle, et al.. (2022). Bortezomib Maintenance After Allogeneic Transplantation in Newly Diagnosed Myeloma Patients Results in Decreased Incidence and Severity of Chronic GVHD. Transplantation and Cellular Therapy. 29(1). 44.e1–44.e9. 2 indexed citations

Lachance, Silvy, Philippe Bouchard, Imran Ahmad, et al.. (2022). Impact of Implementing a Bendamustine-Based Conditioning Regimen on Outcomes of Autologous Stem Cell Transplantation in Lymphoma while Novel Cellular Therapies Emerge. Transplantation and Cellular Therapy. 29(1). 34.e1–34.e7. 7 indexed citations

Trofimov, Assya, Jonathan Séguin, Jean‐Philippe Laverdure, et al.. (2022). Two types of human TCR differentially regulate reactivity to self and non-self antigens. iScience. 25(9). 104968–104968. 11 indexed citations

Hébert, Josée, Lambert Busque, François Mercier, et al.. (2022). Blasts in context: the impact of the immune environment on acute myeloid leukemia prognosis and treatment. Blood Reviews. 57. 100991–100991. 14 indexed citations

LeBlanc, Richard, Imran Ahmad, David Ogez, et al.. (2021). Outcomes in newly diagnosed young or high-risk myeloma patients receiving tandem autologous/allogeneic transplant followed by bortezomib maintenance: a phase II study. Bone Marrow Transplantation. 57(2). 252–260. 6 indexed citations

10.

Ahmad, Imran, Nadia M. Bambace, Léa Bernard, et al.. (2019). Outcome of autologous hematopoietic stem cell transplant in older patients with B cell lymphoma when selected for fitness and chemosensitive disease. Leukemia Research. 79. 75–80. 8 indexed citations

11.

Ahmad, Imran, Nadia M. Bambace, Léa Bernard, et al.. (2019). Evaluation of the Impact of Autologous Hematopoietic Stem Cell Transplantation on the Quality of Life of Older Patients with Lymphoma. Biology of Blood and Marrow Transplantation. 26(1). 157–161. 14 indexed citations

12.

Bouchard, Philippe, Sandra Cohen, Imran Ahmad, et al.. (2017). Impact of Carmustine (BCNU) Substitution for Bendamustine in the Conditioning Regimen Prior to Autologous Hematopoietic Cell Transplantation for the Treatment of Lymphoma. Blood. 130. 2022–2022. 2 indexed citations

13.

Bubela, Tania, et al.. (2017). More Haste, Less Speed: Could Public–Private Partnerships Advance Cellular Immunotherapies?. Frontiers in Medicine. 4. 134–134. 5 indexed citations

14.

LeBlanc, Richard, Imran Ahmad, J. Ferreira, et al.. (2017). Cerebral adenovirus endotheliitis presenting as posterior reversible encephalopathy syndrome after allogeneic stem cell transplantation. Bone Marrow Transplantation. 52(10). 1457–1459. 6 indexed citations

15.

Krakow, Elizabeth F., Julie Bergeron, Silvy Lachance, Denis‐Claude Roy, & Jean‐Sébastien Delisle. (2014). Harnessing the power of alloreactivity without triggering graft-versus-host disease: how non-engrafting alloreactive cellular therapy might change the landscape of acute myeloid leukemia treatment. Blood Reviews. 28(6). 249–261. 9 indexed citations

16.

Roy, Jean, et al.. (2012). Defining the Role of Sirolimus in the Management of Graft-versus-Host Disease: From Prophylaxis to Treatment. Biology of Blood and Marrow Transplantation. 19(1). 12–21. 39 indexed citations

17.

Sabry, Waleed, Richard Le Blanc, Annie‐Claude Labbé, et al.. (2009). Graft-versus-Host Disease Prophylaxis with Tacrolimus and Mycophenolate Mofetil in HLA-Matched Nonmyeloablative Transplant Recipients Is Associated with Very Low Incidence of GVHD and Nonrelapse Mortality. Biology of Blood and Marrow Transplantation. 15(8). 919–929. 30 indexed citations

18.

Labbé, Annie‐Claude, Michél Laverdière, Jean‐Louis Pépin, et al.. (2007). High Incidence of Invasive Aspergillosis Associated with Intestinal Graft-versus-Host Disease following Nonmyeloablative Transplantation. Biology of Blood and Marrow Transplantation. 13(10). 1192–1200. 40 indexed citations

19.

Bernatsky, Sasha, Rosalind Ramsey‐Goldman, Silvy Lachance, Christian A. Pineau, & Ann E. Clarke. (2006). Lymphoma in a patient with systemic lupus erythematosus. Nature Clinical Practice Rheumatology. 2(10). 570–574. 3 indexed citations

20.

Lachance, Silvy, Mathieu Kuentz, F. Beaujean, et al.. (1997). PREDICTIVE VALUE OF HOST-SPECIFIC DONOR HELPER T-CELL PRECURSOR FREQUENCY FOR ACUTE GRAFT-VERSUS-HOST DISEASE AND RELAPSE IN HLA-IDENTICAL SIBLINGS RECEIVING ALLOGENEIC BONE MARROW TRANSPLANTATION FOR HEMATOLOG. Transplantation. 64(8). 1147–1152. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact